ArticleMedical science monitor : international medical journal of experimental and clinical research2023
Risk Factors for Mortality in Severe Fever with Thrombocytopenia Syndrome Patients with Central Nervous System Complications.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Cytokine Indicators Associated with Disease Severity in Severe Fever with Thrombocytopenia Syndrome: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2026Pooled it
- CT-detected lymphadenopathy and prognostic markers in severe fever with thrombocytopenia syndrome: a retrospective study.BMC infectious diseases · 2026Article
- Early plasma exchange for severe fever with thrombocytopenia syndrome (SFTS)-associated encephalopathy and multi-organ dysfunction syndrome (MODS): a case report.BMC infectious diseases · 2026Article
- Neurological Manifestations and High Viral Load as Independent Predictors of Mortality in Severe Fever With Thrombocytopenia Syndrome.Open forum infectious diseases · 2026Article
- Prediction models for encephalitis and in-hospital death associated with severe fever with thrombocytopenia syndrome.BMC infectious diseases · 2025Article
- Retrospective Analysis of Severe Fever With Thrombocytopenia Syndrome and Construction of a Nomogram Prediction Model for Mortality Risk Factors.Open forum infectious diseases · 2025Article
- Tick-Borne Infectious Diseases in China, 2003-2023.China CDC weekly · 2025Review
- Intensive care unit-based mortality risk model construction for severe fever with thrombocytopenia syndrome patients: a retrospective study.BMC infectious diseases · 2025Article
- Alarming implications: severe fever with thrombocytopenia syndrome and its biological vectors in the context of climate change.Frontiers in microbiology · 2025Review
- The hnRNP A2B1 is important for the replication of SFTSV and other RNA viruses.Microbiology spectrum · 2024Article
- Early predictors of Epstein-Barr virus infection in patients with severe fever with thrombocytopenia syndrome.Virology journal · 2024Article
- Severe fever with thrombocytopenia syndrome with central nervous system symptom onset: a case report and literature review.BMC neurology · 2024Review
- Aspartate aminotransferase to platelet ratio correlates with poor prognosis and metabolic alterations inFrontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Severe fever with thrombocytopenia syndrome (SFTS) is a zoonotic viral hemorrhagic fever caused by the SFTS virus (SFTSV), which is a newly identified tick-borne bunyavirus, recently named Dabie bandavirus. In rural China, SFTSV or Dabie bandavirus is commonly transmitted by Haemaphysalis longicornis, the Asian longhorned tick. In recent years, SFTS has been of great concern due to its high morbidity and mortality. The present study investigated the risk factors for mortality in patients with SFTS complicated by central nervous system involvement. MATERIAL AND METHODS We studied 69 SFTS patients hospitalized between 2013 and 2020. We analyzed the laboratory test results and clinical data through univariate and multivariate regression. RESULTS Neurological complications occurred in 59 patients in the survival group and 10 in the mortality group. No significant gender difference was found between the 2 groups. No significant difference was found in age, hospitalization duration, or occurrence of encephalitis between the 2 groups. The mean duration of hospitalization and course of the disease in the mortality group were significantly shorter than those in the survival group (P<0.01). The mean values of platelet count, potassium, and sodium in the mortality group were significantly lower, while the mean values of aspartate aminotransferase, lactic dehydrogenase, creatine kinase-MB (CK-MB) and procalcitonin were higher than those in the survival group. Low platelet count and high CK-MB were independent risk factors for mortality in patients. For each unit increase in platelet count, the risk of mortality decreased by 24.2%, and for each unit increase in CK-MB, the probability of mortality increased by 118.6%. CONCLUSIONS Decreased platelets and increased CK-MB were independent risk factors for mortality in encephalitis patients. SFTS patients with encephalitis should be monitored for changes in these 2 indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.